Matrix metalloproteinase-3 in preeclamptic and normotensive pregnancies complicated by foetal growth restriction

Marzena Laskowska; Weronika Dymara-Konopka; Elżbieta Szmit; Dominika Ledwich-Kibicka; Andrzej Wróbel

doi:10.1016/j.heliyon.2023.e18105

Matrix metalloproteinase-3 in preeclamptic and normotensive pregnancies complicated by foetal growth restriction

Heliyon. 2023 Jul 7;9(7):e18105. doi: 10.1016/j.heliyon.2023.e18105. eCollection 2023 Jul.

Authors

Marzena Laskowska¹, Weronika Dymara-Konopka¹, Elżbieta Szmit², Dominika Ledwich-Kibicka², Andrzej Wróbel³

Affiliations

¹ Department of Obstetrics and Perinatology, Medical University of Lublin, Jaczewskiego 8, 20-095, Lublin, Poland.
² Neonatology Division of Clinical Public Hospital, No 4 in Lublin, Jaczewskiego 8, 20-095, Lublin, Poland.
³ Second Department of Gynaecology, Medical University of Lublin, Jaczewskiego 8, 20-095, Lublin, Poland.

Abstract

The aim of the present study was to assess the interrelationships between the level of matrix metalloproteinase-3 in the blood serum of pregnant women and the occurrence of pregnancy complications in the form of foetal growth restriction, idiopathic or in the course of preeclampsia.

Methods: A total of 245 patients were included in the study. 65 of them are normotensive patients with idiopathic foetal growth restriction (FGR group). 115 women were diagnosed with severe preeclampsia. In the group of women with preeclampsia, there were 51 patients with adequate for gestational age foetal growth and 64 patients with the foetal growth restriction in the course of severe preeclampsia. The control group consisted of 65 healthy patients with normal pregnancy course, with no cardiovascular disorders at the present and in the history, normal blood pressure and normal intrauterine foetal growth. Matrix metalloproteinase-3 (MMP-3) in maternal circulation were determined by ELISA method.

Results: In our studies, we observed elevated levels of matrix metalloproteinase-3 in preeclamptic women with pregnancies complicated by FGR and significantly lower in the group of normotensive women with idiopathic FGR. The mean values of MMP-3 were 33.50 ± 65.74 ng/mL [Median (min-max) 19.19 (2.05-454.53)] in the Control group, 21.22 ± 23.28 ng/mL [Median (min-max) 16.39 (3.45-156.29)] in the FGR group, 35.96 ± 46.14 ng/mL [Median (min-max) 25.21 (4.16-253.05)] in the P group and 52.81 ± 61.61 ng/mL [Median (min-max) 32.83 (5.06-314.14)] in preeclamptic women with FGR (group PI) respectively.The assessment of MMP-3 in the serum of women with pregnancies complicated by intrauterine foetal growth restriction with normal values of blood pressure and in the group of preeclamptic patients in relation to healthy pregnant women with uncomplicated pregnancies and in relation to preeclamptic patients with normal intrauterine foetal growth is the novelty of this study. Such a strict definition of each research group seems to allow for the assessment of each pregnancy complication separately.

Conclusion: It seems that higher levels of MMP-3 in preeclamptic women may suggest the need for observation towards the risk of lower birth weight of newborns. This necessitates further research and a better integration in the clinical practice.

Keywords: Foetal growth restriction (FGR); Idiopathic FGR; Matrix metalloproteinase-3 (MMP-3); Severe preeclampsia.